Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0033687 (proteinuria)
 24,015 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

D-penicillamine (DPA) leads to side effects in different ways: collagen and elastin crosslinking are inhibited, which results in thin and vulnerable skin, cutis laxa, elastosis perforans serpiginosa, wound healing defects and embryopathy. Toxic influences effect thrombo- and leukocytopenia (incidence 5-15%), gastrointestinal disturbances (10-30%), changes or loss of taste (5-30%), loss of hair (1-2%), and partly proteinuria (5-20%). Acute hypersensitive reactions include DPA-allergy (2-10%). Severe adverse effects are autoimmune phenomena such as pemphigus, DPA-induced lupus erythematosus, polymyositis/dermatomyositis, membranous glomerulopathy and hypersensitivity pneumonitis (like Good-pasture's syndrome) and myasthenia (all less than 1%). In addition there are a number of rare side effects, often single observations. Risk factors include a genetic disposition (especially HLA-B8 and -DR3), poor sulphoxidizers and, to a certain degree, higher age. During pregnancy and in clinically relevant disturbances of bone marrow, liver and renal function DPA is contraindicated. The total incidence of side effects amounts to 30-60%, the withdrawal rate is 20-30%; therefore clear indications and a regular survey of DPA therapy are necessary.
 ...
PMID:[D-penicillamine--side effects, pathogenesis and decreasing the risks]. 306 3

Myasthenia gravis is caused by antibodies against acetylcholine receptors and is treated with inhibition or elimination of antibody production. We report a 43-year-old myasthenic female who was symptomatic until she developed proteinuria from nephrotic syndrome, which caused a marked drop in acetylcholine receptor antibody titer with remission of myasthenia. Treatment of the nephrotic syndrome produced exacerbation of her myasthenia and a rise in antibody level. This patient's improvement is the result of antibody elimination during proteinuria in nephrotic syndrome.
 ...
PMID:Remission of myasthenia gravis caused by proteinuria in nephrotic syndrome. 939 Jun 72

Nephropathies associated with thymoma or myasthenia gravis (MG) have rarely been observed. Furthermore, among the renal pathology of patients presenting with thymic and renal disease, focal segmental glomerulonephritis (FSGS) is the uncommon type. Herein, we report a case of a 50-year-old woman who suffered from intractable MG and FSGS resistant to standard therapy. After the start of low-dose tacrolimus treatment, the patient showed simultaneous and significant improvement of myasthenic symptoms and proteinuria. Although a satisfactory explanation of the underlying mechanism has not been offered yet, T cell dysfunction involved in both diseases might explain their association and improvement. This case suggests that low-dose tacrolimus treatment appears to be effective not only for improving intractable myasthenia symptoms but also for obtaining complete remission of FSGS.
 ...
PMID:Simultaneous and sustained remission of intractable myasthenia gravis and focal segmental glomerulosclerosis with tacrolimus treatment. 1879 50